OR WAIT null SECS
July 21, 2023
Under a global license agreement, Bristol Myers Squibb and Evotec will advance the development of neurodegeneration pipeline assets.
May 12, 2023
In a deal potentially worth more than $530 million, Amgen will use TScan Therapeutics’ target discovery platform to home in on novel targets for Crohn’s disease treatment.
April 14, 2023
Ginkgo Bioworks has acquired StrideBio's AAV capsid discovery and engineering platform and has formed a partnership with WARF for development of next-gen cell therapies.
The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.
March 22, 2023
Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.
March 17, 2023
The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.
January 18, 2023
Pfizer and Gero have partnered to discover potential therapeutic targets for fibrotic diseases using machine learning technology.
The collaboration between AbbVie and Anima Biotech will combine Anima's mRNA Lightning technology platform with AbbVie's extensive expertise in oncology and immunology.
December 19, 2022
GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.
AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.